The present invention is directed to compounds of Formula I: wherein X is CR.sub.1 or N; Y is CR.sub.2 or N; Z is NH or O; R.sub.1 is alkoxy, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrimidinyl; R.sub.2 is H, alkyl, or halo; R.sub.3 is H, alkyl, alkoxy, halo, triazolyl, oxazolyl, or pyrimidinyl; R.sub.4 is alkyl; R.sub.5 is pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl; wherein the pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl is optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, or phenyl; and R.sub.6 is H or alkyl. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods using the compounds of the invention are also within the scope of the invention. ##STR00001##

The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.

##STR00001##

A combination therapy including one or more compounds of formula (I): ##STR00001##
wherein R represents hydrogen, halo, cyano, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, or SO.sub.2NR.sup.5R.sup.6, R.sup.1a and R.sup.1b independently represent hydrogen or halo; R.sup.2 represents hydrogen, halo, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or C.sub.1-4 haloalkoxy; R.sup.3 represents halo, cyano, C.sub.1-4 alkyl, or C.sub.1-4 hydroxyalkyl; R.sup.4 represents hydrogen or C.sub.1-4 alkyl; X represents CH or N; Y represents N or CH which carbon atom may optionally be substituted by R, R.sup.1a or R.sup.1b; R.sup.5 and R.sup.6 independently represent hydrogen or C.sub.1-4 alkyl; or a pharmaceutically acceptable salt thereof; and a second or further active ingredient.

A combination therapy including one or more compounds of formula (I): ##STR00001##
wherein R represents hydrogen, halo, cyano, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, or SO.sub.2NR.sup.5R.sup.6, R.sup.1a and R.sup.1b independently represent hydrogen or halo; R.sup.2 represents hydrogen, halo, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or C.sub.1-4 haloalkoxy; R.sup.3 represents halo, cyano, C.sub.1-4 alkyl, or C.sub.1-4 hydroxyalkyl; R.sup.4 represents hydrogen or C.sub.1-4 alkyl; X represents CH or N; Y represents N or CH which carbon atom may optionally be substituted by R, R.sup.1a or R.sup.1b; R.sup.5 and R.sup.6 independently represent hydrogen or C.sub.1-4 alkyl; or a pharmaceutically acceptable salt thereof; and a second or further active ingredient.

An aryl phosphine with fused ring ortho-alkoxy substitution that includes an aryl monophosphine and an aryl bi-sphosphme.

This invention relates to a compound, as defined in the specification, useful in the treatment of mycoses, compositions containing it and its use in therapy.

The present invention relates to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways. ##STR00001##

This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

Compounds of formula (I), and related aspects. ##STR00001##

Compounds of formula (I), and related aspects. ##STR00001##